JII COMPOUNDERS · CAPITAL-ALLOCATION SIGNAL LOG

Matsuya R&D Co.,Ltd (7317)

· Standing universe

3 signals on file · latest 2026-06-25

2026-06-25 · 15:35 JSTTake-private / tender offer

MBO - Omron Healthcare / 20.73M shares (95.88% post-tender) - ¥1,110/share - Squeeze-out (Article 179) - Delisting 2026-07-17

¥1,110/share squeeze-out (Article 179 CBCA) by Omron Healthcare (95.88% post-tender). Demand notice issued 2026-06-25. Remaining minority shareholders compelled to sell all ordinary shares; warrant holders compelled to sell all warrants (¥717,600/warrant). Trading suspended 2026-07-16 (consolidation); delisting 2026-07-17. Settlement 2026-07-22.

2026-06-16 · 15:35 JSTTake-private / tender offer

MBO — Omron Healthcare acquisition of Matsuya R&D — 17.57M shares (81.3% S/O) — JPY not disclosed — Tender offer completed 2026-06-15

Omron Healthcare tender offer for Matsuya R&D completed 2026-06-15. 17,567,455 shares tendered (81.3% of shares outstanding ex-treasury). Offer acceptance threshold minimum 11,230,300 shares exceeded. Settlement 2026-06-19. Omron Healthcare becomes majority shareholder and parent company; Omron Corp becomes indirect parent. Prior shareholders Michihiro Goto and Masahiro Goto tender all holdings, cease to be principal shareholders.

2026-05-18 · 16:30 JSTTake-private / tender offer

MBO · Omron Healthcare acquisition · 11.23M shares minimum · ¥1,110/share · Delisting planned

Matsuya R&D's board reaffirms support for Omron Healthcare's tender offer to acquire the company as a wholly-owned subsidiary at ¥1,110 per share, with a minimum purchase of 11.23M shares and planned delisting.

Important Disclaimer · 重要なご注意

This is not investment advice.

Japan Investor Interface Co., Ltd. ("JII") is an investor-relations (IR) consultancy. JII is not a registered investment advisor, financial advisor, broker-dealer, or securities firm in any jurisdiction, and is not registered as a Financial Instruments Business Operator (金融商品取引業者) under Japan's Financial Instruments and Exchange Act. JII does not provide investment advice or solicit the purchase, sale, or holding of any security.

JII Compounders is an editorial publication. Each profile and this signal log are analytical studies of how publicly disclosed information about Japanese listed companies has been received by the market, for educational and research purposes. Nothing here constitutes a recommendation or solicitation to buy, sell, or hold any security. JII does not have an investment opinion on any security discussed.

No reliance. The information may be incomplete, out of date, or incorrect. Past price performance does not indicate future results. Before any investment, tax, accounting, or legal decision, consult qualified, licensed advisors and conduct your own due diligence based on the company's primary disclosures.

Conflicts & positions. JII may provide paid IR services to Japanese listed companies, including companies discussed here. JII does not trade in or hold positions in the securities of companies profiled. Any engagement with a profiled company is disclosed at the top of that profile.

本資料は投資助言・代理業ではなく、特定の有価証券の売買の勧誘・推奨を目的とするものではありません。教育・研究を目的とした分析記事です。